Nektar Therapeutics (NKTR)

20.70
0.52 2.45
NASDAQ : Health Technology
Prev Close 21.22
Open 21.24
Day Low/High 20.26 / 21.32
52 Wk Low/High 16.56 / 66.95
Volume 3.01M
Avg Volume 2.56M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 3.49B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Moving On Up

Even though sellers knocked prices down in the afternoon, it will take more than that to stop the current rally.

Turnaround Still Possible

Despite getting sucker-punched, buyers haven't yet been given enough time or opportunity to lose faith and give up.

Movers Roundup: Rite Aid, Nektar Therapeutics

Movers Roundup: Rite Aid, Nektar Therapeutics

Movers roundup: Rite Aid downgraded, Nektar drug candidate effective in early study

Nektar Climbs On Trial Data And Partnership

Nektar Climbs On Trial Data And Partnership

Nektar Therapeutics sets two-year high as ovarian cancer drug data follows AstraZeneca pact

Health Care Funds Get Obama Bounce

Health Care Funds Get Obama Bounce

The average health care fund rose 1.5% in the past week as investors mulled Obama's health care plan.

Nektar Shares Rise On Morgan Joseph Analyst View

Nektar Shares Rise On Morgan Joseph Analyst View

Nektar Therapeutics shares rise as Morgan Joseph analyst maintains positive outlook

Nektar Shares Rise As Partner Gets FDA Approval

Nektar Shares Rise As Partner Gets FDA Approval

Nektar Therapeutics shares rise as partner receives FDA approval on potential blockbuster

RA Patients Choose Pain Over Poverty: Survey

The weakened economy is causing rheumatoid arthritis patients to put off or delay treatment with expensive injectable drugs and pressuring the leading market players.

Health Winners & Losers: Omrix

Seattle Genetics rises, but Alnylam falls.

Novartis to Buy Nektar's Pulmonary Business

Novartis to Buy Nektar's Pulmonary Business

The Swiss drug maker will acquire the assets for $115 million in cash.

Jim Cramer's Best Blogs

Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Millennium Pharma surges on buyout news.

Wednesday's Winners & Losers: MannKind

Wednesday's Winners & Losers: MannKind

Shares plummet on fears the company's main drug will fail.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Nektar and MannKind tumble on inhaled insulin drug data.

Inhaled Insulin Dependence Leaves MannKind Gasping

Shares of the biotech free fall on fears its lead drug candidate may never make it to market.

Nektar Gives Up on Inhaled Insulin

Latest study data serve as the death knell for the Exubera program, and also send shares of competitor Mannkind lower.

Stock Upgrades, Downgrades From TheStreet.com Ratings

Stock Upgrades, Downgrades From TheStreet.com Ratings

Nektar, CTC Media upgraged; Brady, Pinnacle West, CNA Surety downgraded.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Earnings lift Medicis and Nektar, but slam PharmaNet and Osiris.

No Easy Fix for Pfizer

No Easy Fix for Pfizer

It can be done, but it will probably require some tough choices.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Tutogen climbs on a merger deal with Regeneration Technologies.

After Exubera, Uncertainty Reigns

Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.

'Fast Money' Recap: Drug Money

'Fast Money' Recap: Drug Money

Mike Huckman joins the crew as pharmas get close to reporting.

Thursday's Small-Cap Winners & Losers

Thursday's Small-Cap Winners & Losers

Accelr8 Technology revs higher.

Pfizer Drops Sluggish Exubera

The company takes a large charge to leave the inhaled insulin product behind, and earnings plunge.

Wednesday's Health Winners & Losers

Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Sangamo BioSciences climbs on animal study results for an HIV treatment.

One Giant Leap for MannKind

The company will sell $350 million in debt, warrants and stock.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Abraxis Bioscience rises on a quarterly revenue increase.

Pfizer: Exubera's Lung Side Effects Temporary

The drugmaker says patients who stop taking inhaled insulin see lung function return to normal in a month.

TheStreet Quant Rating: D (Sell)